Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on hydrochlorothiazide to olmesartan + amlodipine in moderate to severe hypertension
NL-OMON35561Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydrochlorothiazide, olmesartan and amlodipine in essential hypertension (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in trough seated diastolic blood pressure at Week 16. Started Dec 2009; status: active, not recruiting.
02
Drugs
hydrochlorothiazideolmesartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NL-OMON35561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35561.